Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Structural Characterisation of Phosphomimetic Mutants of Tau in Alzheimer's Disease

FY 2023-24

Summary
Over 7 million people are living with Alzheimer’s in Canada, which makes it a notable crisis to be addressed. Alzheimer’s is strongly linked to the abnormal folding or aggregation of two proteins in the brain: amyloid beta and tau. Tau binds and stabilizes microtubules in the neurons. The predominant reason for tau aggregation is hyperphosphorylation. Phosphorylation is the most prevalent post-transcriptional modification that tau undergoes. Tau performs a normal function when equilibrium is maintained between phosphokinases which add phosphate groups, and phosphatases which remove phosphate groups. When this balance is disturbed, tau’s intracellular interactions are modulated, which makes it to detach from microtubules and aggregate as ‘clumps’ known as neurofibrillary tangles (NFTs). The exact mechanism on how phosphorylation affects tau aggregation still remains unclear because tau has over 70 phosphorylation prone sites and the pattern is dynamic. The purpose of our research is to understand how tau aggregate structures due to phosphorylation contribute to disease progression. Since phosphorylation of tau does not happen at the same time at all the sites, it is important to study the effect of phosphorylation at one site at a time to elucidate the key aggregation parameters. To achieve this, we will sequentially mutate serine and threonine residues of tau to glutamate, which is chemically similar to the phosphorylated amino acids. With this library of mutants, studying the structures arising from the mutations will give clarity on how abnormal tau have recruited or modulated other tau towards disease progression. This research will allow us to understand how structures play towards disease progression and these features could be exploited for therapeutic approaches.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506268
Name
Srinivasan Mahalashmi
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Structural Characterisation of Phosphomimetic Mutants of Tau in Alzheimer's Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Cellular Seeding; High Throughput; Mutation Screening; Phosphorylation; Protein Aggregation; Protein Purification; Tauopathies
Abstract
Over 7 million people are living with Alzheimer’s in Canada, which makes it a notable crisis to be addressed. Alzheimer’s is strongly linked to the abnormal folding or aggregation of two proteins in the brain: amyloid beta and tau. Tau binds and stabilizes microtubules in the neurons. The predominant reason for tau aggregation is hyperphosphorylation. Phosphorylation is the most prevalent post-transcriptional modification that tau undergoes. Tau performs a normal function when equilibrium is maintained between phosphokinases which add phosphate groups, and phosphatases which remove phosphate groups. When this balance is disturbed, tau’s intracellular interactions are modulated, which makes it to detach from microtubules and aggregate as ‘clumps’ known as neurofibrillary tangles (NFTs). The exact mechanism on how phosphorylation affects tau aggregation still remains unclear because tau has over 70 phosphorylation prone sites and the pattern is dynamic. The purpose of our research is to understand how tau aggregate structures due to phosphorylation contribute to disease progression. Since phosphorylation of tau does not happen at the same time at all the sites, it is important to study the effect of phosphorylation at one site at a time to elucidate the key aggregation parameters. To achieve this, we will sequentially mutate serine and threonine residues of tau to glutamate, which is chemically similar to the phosphorylated amino acids. With this library of mutants, studying the structures arising from the mutations will give clarity on how abnormal tau have recruited or modulated other tau towards disease progression. This research will allow us to understand how structures play towards disease progression and these features could be exploited for therapeutic approaches.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Srinivasan, Mahalashmi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~